Literature DB >> 7613471

Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A).

B A McMullen1, K Fujikawa, E W Davie, U Hedner, M Ezban.   

Abstract

The locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII were determined by sequence analysis of fragments produced by chemical and enzymatic digestions. The A1 and A2 domains of the heavy chain and the A3 domain of the light chain contain one free cysteine and two disulfide bonds, whereas the C1 and C2 domains of the light chain have one disulfide bond and no free cysteine. The positions of these disulfide bonds are conserved in factor V and ceruloplasmin except that the second disulfide bond in the A3 domain is missing in both factor V and ceruloplasmin. The positions of the three free cysteines of factor VIII are the same as three of the four cysteines present in ceruloplasmin. However, the positions of the free cysteines in factor VIII and ceruloplasmin are not conserved in factor V.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7613471      PMCID: PMC2143093          DOI: 10.1002/pro.5560040413

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  11 in total

1.  Disulphide interchange reactions.

Authors:  A P RYLE; F SANGER
Journal:  Biochem J       Date:  1955-08       Impact factor: 3.857

2.  The functional domains of coagulation factor VIII:C.

Authors:  R L Burke; C Pachl; M Quiroga; S Rosenberg; N Haigwood; O Nordfang; M Ezban
Journal:  J Biol Chem       Date:  1986-09-25       Impact factor: 5.157

Review 3.  Biological regulation of factor VIII activity.

Authors:  R J Kaufman
Journal:  Annu Rev Med       Date:  1992       Impact factor: 13.739

4.  Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine.

Authors:  P A Foster; C A Fulcher; R A Houghten; T S Zimmerman
Journal:  Blood       Date:  1990-05-15       Impact factor: 22.113

5.  A procedure for in situ alkylation of cystine residues on glass fiber prior to protein microsequence analysis.

Authors:  P C Andrews; J E Dixon
Journal:  Anal Biochem       Date:  1987-03       Impact factor: 3.365

6.  The role of phospholipid and factor VIIIa in the activation of bovine factor X.

Authors:  G van Dieijen; G Tans; J Rosing; H C Hemker
Journal:  J Biol Chem       Date:  1981-04-10       Impact factor: 5.157

7.  Single-chain structure of human ceruloplasmin: the complete amino acid sequence of the whole molecule.

Authors:  N Takahashi; T L Ortel; F W Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

8.  Intersubunit fluorescence energy transfer in human factor VIII.

Authors:  P J Fay; T M Smudzin
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

9.  Determination of the disulfide bridges in factor Va heavy chain.

Authors:  J Xue; M Kalafatis; J R Silveira; C Kung; K G Mann
Journal:  Biochemistry       Date:  1994-11-08       Impact factor: 3.162

10.  Characterization of the polypeptide composition of human factor VIII:C and the nucleotide sequence and expression of the human kidney cDNA.

Authors:  M A Truett; R Blacher; R L Burke; D Caput; C Chu; D Dina; K Hartog; C H Kuo; F R Masiarz; J P Merryweather
Journal:  DNA       Date:  1985-10
View more
  11 in total

1.  Correlation of rFVIII inactivation with aggregation in solution.

Authors:  Wei Wang; Drew N Kelner
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

2.  Proteolytic cleavage of recombinant two-chain factor VIII during cell culture production is mediated by protease(s) from lysed cells. The use of pulse labelling directly in production medium.

Authors:  K Hansen; M Kjalke; P B Rasmussen; L Kongerslev; M Ezban
Journal:  Cytotechnology       Date:  1997-09       Impact factor: 2.058

3.  pH-dependent association of factor VIII chains: enhancement of affinity at physiological pH by Cu2+.

Authors:  Hironao Wakabayashi; Qian Zhou; Keiji Nogami; Charles Ansong; Fatbardha Varfaj; Stephen Miles; Philip J Fay
Journal:  Biochim Biophys Acta       Date:  2006-04-22

4.  Specific inhibition of ectodomain shedding of glycoprotein Ibα by targeting its juxtamembrane shedding cleavage site.

Authors:  X Liang; S R Russell; S Estelle; L H Jones; S Cho; M L Kahn; M C Berndt; S T Bunting; J Ware; R Li
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

5.  Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop.

Authors:  S R Selvaraj; A N Scheller; H Z Miao; R J Kaufman; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2012-01       Impact factor: 5.824

6.  Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.

Authors:  A M Sevy; J F Healey; W Deng; P C Spiegel; S L Meeks; R Li
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

7.  Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor.

Authors:  Jing-Jiang Wu; Kazuo Fujikawa; Brad A McMullen; Dominic W Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-22       Impact factor: 11.205

8.  A proximity-based in silico approach to identify redox-labile disulfide bonds: The example of FVIII.

Authors:  Andrea Arsiccio; Clive Metcalfe; Roberto Pisano; Sanj Raut; Carmen Coxon
Journal:  PLoS One       Date:  2022-02-07       Impact factor: 3.240

9.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25

10.  Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.

Authors:  Keiji Nogami; Midori Shima; John C Giddings; Masahiro Takeyama; Ichiro Tanaka; Akira Yoshioka
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.